United Services Automobile Association Acquires New Position in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• United Services Automobile Association has acquired a new stake of 2,477 shares in Regeneron Pharmaceuticals, valued at approximately $1.58 million during the first quarter.
• Regeneron reported strong quarterly earnings with an EPS of $12.89, significantly beating analysts' expectations of $8.43, and showing a revenue of $3.68 billion, which exceeded forecasts.
• The company recently announced a quarterly dividend of $0.88, resulting in an annualized dividend of $3.52 and a yield of 0.6%.

United Services Automobile Association acquired a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 2,477 shares of the biopharmaceutical company's stock, valued at approximately $1,579,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in REGN. Adirondack Trust Co. grew its position in Regeneron Pharmaceuticals by 4.2% in the first quarter. Adirondack Trust Co. now owns 451 shares of the biopharmaceutical company's stock worth $286,000 after acquiring an additional 18 shares in the last quarter. Kingswood Wealth Advisors LLC grew its position in Regeneron Pharmaceuticals by 1.8% in the first quarter. Kingswood Wealth Advisors LLC now owns 1,084 shares of the biopharmaceutical company's stock worth $681,000 after acquiring an additional 19 shares in the last quarter. Creative Financial Designs Inc. ADV grew its position in Regeneron Pharmaceuticals by 9.5% in the first quarter. Creative Financial Designs Inc. ADV now owns 220 shares of the biopharmaceutical company's stock worth $139,000 after acquiring an additional 19 shares in the last quarter. Private Trust Co. NA grew its position in Regeneron Pharmaceuticals by 13.1% in the first quarter. Private Trust Co. NA now owns 164 shares of the biopharmaceutical company's stock worth $104,000 after acquiring an additional 19 shares in the last quarter. Finally, Proficio Capital Partners LLC grew its position in Regeneron Pharmaceuticals by 6.2% in the first quarter. Proficio Capital Partners LLC now owns 327 shares of the biopharmaceutical company's stock worth $207,000 after acquiring an additional 19 shares in the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms recently issued reports on REGN. Argus downgraded shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Monday, June 30th. Rothschild & Co Redburn began coverage on shares of Regeneron Pharmaceuticals in a report on Thursday, August 14th. They set a "buy" rating and a $890.00 price objective for the company. Sanford C. Bernstein upped their price objective on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the stock an "outperform" rating in a report on Wednesday, August 27th. UBS Group reaffirmed a "neutral" rating on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Finally, Guggenheim upped their price objective on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $817.67.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $573.38 on Monday. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,170.58. The stock has a market cap of $60.77 billion, a P/E ratio of 14.45, a PEG ratio of 1.92 and a beta of 0.35. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. The company has a fifty day moving average price of $562.59 and a 200 day moving average price of $583.13.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company had revenue of $3.68 billion during the quarter, compared to analysts' expectations of $3.30 billion. During the same quarter in the prior year, the company posted $11.56 EPS. The business's revenue was up 3.6% on a year-over-year basis. Analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were paid a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.87%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.